These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 22742720

  • 1. Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial.
    Bleskestad IH, Bergrem H, Hartmann A, Godang K, Gøransson LG.
    BMC Nephrol; 2012 Jun 28; 13():49. PubMed ID: 22742720
    [Abstract] [Full Text] [Related]

  • 2. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
    Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G, FRENCH Study collaborators.
    Clin J Am Soc Nephrol; 2017 Dec 07; 12(12):1930-1940. PubMed ID: 29074818
    [Abstract] [Full Text] [Related]

  • 3. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B, Trillini M, Tartaglione L, Rotondi S, Perticucci E, Tripepi R, Aparicio C, Lecchi V, Perna A, Peraro F, Villa D, Ferrari S, Cannata A, Mazzaferro S, Mallamaci F, Zoccali C, Bellasi A, Cozzolino M, Remuzzi G, Ruggenenti P, Kohan DE, ANSWER Study Organization.
    Am J Kidney Dis; 2019 Sep 07; 74(3):338-350. PubMed ID: 31027883
    [Abstract] [Full Text] [Related]

  • 4. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
    Phelps KR, Stote KS, Mason D.
    Clin Nephrol; 2014 Sep 07; 82(3):191-201. PubMed ID: 25079864
    [Abstract] [Full Text] [Related]

  • 5. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C, Roe K, Lehman E, Verma N.
    Nephron Clin Pract; 2013 Sep 07; 123(1-2):61-6. PubMed ID: 23774446
    [Abstract] [Full Text] [Related]

  • 6. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?
    Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM.
    Clin J Am Soc Nephrol; 2010 Feb 07; 5(2):286-91. PubMed ID: 19965540
    [Abstract] [Full Text] [Related]

  • 7. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
    Ureña-Torres P, Prié D, Keddad K, Preston P, Wilde P, Wan H, Copley JB.
    BMC Nephrol; 2014 May 05; 15():71. PubMed ID: 24885942
    [Abstract] [Full Text] [Related]

  • 8. Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly.
    Chudek J, Kocełak P, Owczarek A, Bożentowicz-Wikarek M, Mossakowska M, Olszanecka-Glinianowicz M, Wiecek A.
    Nephrol Dial Transplant; 2014 Sep 05; 29(9):1757-63. PubMed ID: 24729016
    [Abstract] [Full Text] [Related]

  • 9. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW.
    Am J Nephrol; 2019 Sep 05; 49(4):284-293. PubMed ID: 30878999
    [Abstract] [Full Text] [Related]

  • 10. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, Floege J.
    Nephron; 2020 Sep 05; 144(9):428-439. PubMed ID: 32585670
    [Abstract] [Full Text] [Related]

  • 11. Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial.
    Ramirez-Sandoval JC, Arvizu-Hernandez M, Cruz C, Vazquez-Cantu B, Rojas-Concha LJ, Tamez L, Reynerio F, Gomez FE, Correa-Rotter R.
    J Nephrol; 2019 Aug 05; 32(4):645-659. PubMed ID: 30888584
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
    Sprague SM, Covic AC, Floege J, Ketteler M, Botha J, Chong EM, Rastogi A.
    Am J Nephrol; 2016 Aug 05; 44(2):104-12. PubMed ID: 27434393
    [Abstract] [Full Text] [Related]

  • 13. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.
    Wesseling-Perry K, Harkins GC, Wang HJ, Sahney S, Gales B, Elashoff RM, Jüppner H, Salusky IB.
    Pediatr Nephrol; 2009 Jul 05; 24(7):1355-61. PubMed ID: 19301038
    [Abstract] [Full Text] [Related]

  • 14. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
    Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K.
    Clin Nephrol; 2012 Sep 05; 78(3):216-23. PubMed ID: 22874110
    [Abstract] [Full Text] [Related]

  • 15. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA, Lim JH, Kim MY, Kim Y, Yang KS, Chung BH, Chung S, Choi BS, Yang CW, Kim YS, Chang YS, Park CW.
    Clin Exp Nephrol; 2015 Apr 05; 19(2):208-15. PubMed ID: 24682550
    [Abstract] [Full Text] [Related]

  • 16. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB.
    Clin J Am Soc Nephrol; 2014 Feb 05; 9(2):344-53. PubMed ID: 24311704
    [Abstract] [Full Text] [Related]

  • 17. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.
    Am J Kidney Dis; 2009 Oct 05; 54(4):619-37. PubMed ID: 19692157
    [Abstract] [Full Text] [Related]

  • 18. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW.
    BMJ Open; 2017 Aug 23; 7(8):e016528. PubMed ID: 28838895
    [Abstract] [Full Text] [Related]

  • 19. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M, Komaba H, Fukagawa M.
    Contrib Nephrol; 2013 Aug 23; 180():110-23. PubMed ID: 23652554
    [Abstract] [Full Text] [Related]

  • 20. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M.
    Kidney Int; 2006 Feb 23; 69(3):531-7. PubMed ID: 16395276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.